Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference
March 11 2024 - 7:00AM
Business Wire
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a
biotechnology company advancing a pipeline of proprietary small
molecule drugs that address oncology and inflammatory diseases,
today announced its VP of Business Development, Dr. Sari Fishman,
will present data from the pancreatic and liver cancer programs
during numerous partnering meetings at the BIO-Europe Spring 2024
in Barcelona, Spain, on Mar 18-27, 2024
(https://informaconnect.com/bioeurope-spring/).
Can-Fite’s pipeline of indications includes Namodenoson for the
treatment of advanced liver cancer and pancreatic cancer; both
indications have been licensed to the Swiss company Ewopharma for
Eastern Europe. The liver cancer indication has been licensed as
well to CMS in China and CKD in South Korea. Piclidenoson has been
out-licensed to Cipher in Canada; Gebro Pharma for Swiss, Spain,
Austria; CMS for China; and Kyongboo for South Korea. Each of the
deals include upfront and milestone payments. The Company’s growing
slate of indications and advanced pipeline are attracting increased
interest from additional potential partners. Focusing on its core
expertise in clinical development, Can-Fite pursues a strategy of
partnering with companies in specific geographic markets that
specialize in pharmaceutical distribution and regional regulatory
approval.
“Advanced liver cancer and pancreatic cancer are Can-Fite’s
clinical-stage indications for Namodenoson and am delighted with
the interest that Namodenoson is raising with companies that will
participate in the Bio Europe Conference and are experts in drug
development and distribution in the oncology arena. The conference
provides us with the opportunity to present our other developments
to lead pharmaceutical companies,” stated Dr. Sari Fishman, VP
Business Development at Can-Fite.
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) is an
advanced clinical stage drug development Company with a platform
technology that addresses multi-billion dollar markets in the
treatment of cancer, liver, and inflammatory disease. One of the
two Company's lead drug candidates, Piclidenoson recently reported
positive topline results in a Phase III trial for psoriasis. A
pivotal Phase III for this drug is expected to commence soon.
Can-Fite's other lead drug for treating cancer and liver diseases,
Namodenoson, is being evaluated in a Phase IIb trial for the
treatment of steatotic liver disease (SLD), a Phase III pivotal
trial for hepatocellular carcinoma (HCC), and the Company is
planning a Phase IIa study in pancreatic cancer. Namodenoson has
been granted Orphan Drug Designation in the U.S. and Europe for its
HCC indication and Fast Track Designation as a second line
treatment for HCC by the U.S. Food and Drug Administration.
Namodenoson has also shown proof of concept to potentially treat
other cancers including colon, prostate, and melanoma. CF602, the
Company's third drug candidate, has shown efficacy in the treatment
of erectile dysfunction. Piclidenoson and Namodenoson have an
excellent safety profile with experience in over 1,600 patients in
clinical studies to date. For more information please visit:
www.canfite.com.
Forward-Looking Statements
This press release may contain forward-looking statements, about
Can-Fite’s expectations, beliefs or intentions regarding, among
other things, its product development efforts, business, financial
condition, results of operations, strategies or prospects. All
statements in this communication, other than those relating to
historical facts, are “forward looking statements”. Forward-looking
statements can be identified by the use of forward-looking words
such as “believe,” “expect,” “intend,” “plan,” “may,” “should” or
“anticipate” or their negatives or other variations of these words
or other comparable words or by the fact that these statements do
not relate strictly to historical or current matters.
Forward-looking statements relate to anticipated or expected
events, activities, trends or results as of the date they are made.
Because forward-looking statements relate to matters that have not
yet occurred, these statements are inherently subject to known and
unknown risks, uncertainties and other factors that may cause
Can-Fite’s actual results, performance or achievements to be
materially different from any future results, performance or
achievements expressed or implied by the forward-looking
statements. Important factors that could cause actual results,
performance or achievements to differ materially from those
anticipated in these forward-looking statements include, among
other things, our history of losses and needs for additional
capital to fund our operations and our inability to obtain
additional capital on acceptable terms, or at all; uncertainties of
cash flows and inability to meet working capital needs; the
initiation, timing, progress and results of our preclinical
studies, clinical trials and other product candidate development
efforts; our ability to advance our product candidates into
clinical trials or to successfully complete our preclinical studies
or clinical trials; our receipt of regulatory approvals for our
product candidates, and the timing of other regulatory filings and
approvals; the clinical development, commercialization and market
acceptance of our product candidates; our ability to establish and
maintain strategic partnerships and other corporate collaborations;
the implementation of our business model and strategic plans for
our business and product candidates; the scope of protection we are
able to establish and maintain for intellectual property rights
covering our product candidates and our ability to operate our
business without infringing the intellectual property rights of
others; competitive companies, technologies and our industry; risks
related to the COVID-19 pandemic and the Russian invasion of
Ukraine; risks related to not satisfying the continued listing
requirements of NYSE American; and statements as to the impact of
the political and security situation in Israel on our business.
More information on these risks, uncertainties and other factors is
included from time to time in the “Risk Factors” section of
Can-Fite’s Annual Report on Form 20-F filed with the SEC on March
30, 2023 and other public reports filed with the SEC and in its
periodic filings with the TASE. Existing and prospective investors
are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. Can-Fite
undertakes no obligation to publicly update or review any
forward-looking statement, whether as a result of new information,
future developments or otherwise, except as may be required by any
applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240311582155/en/
Can-Fite BioPharma Motti Farbstein info@canfite.com
+972-3-9241114
Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From Mar 2024 to Apr 2024
Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From Apr 2023 to Apr 2024